

Michael G Tovey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3859903/publications.pdf>

Version: 2024-02-01

97
papers

3,891
citations

147801

31
h-index

138484

58
g-index

123
all docs

123
docs citations

123
times ranked

4059
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma. <i>Frontiers in Immunology</i> , 2020, 11, 515556.	4.8	5
2	A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-19.	2.2	15
3	Production of TNF-alpha ex vivo is predictive of an immune response to flu vaccination in a frail elderly population. <i>European Cytokine Network</i> , 2016, 27, 63-67.	2.0	1
4	IFNAR signaling directly modulates T lymphocyte activity, resulting in milder experimental autoimmune encephalomyelitis development. <i>Journal of Leukocyte Biology</i> , 2016, 99, 175-188.	3.3	12
5	Upon Intranasal Vesicular Stomatitis Virus Infection, Astrocytes in the Olfactory Bulb Are Important Interferon Beta Producers That Protect from Lethal Encephalitis. <i>Journal of Virology</i> , 2015, 89, 2731-2738.	3.4	64
6	Introduction: Lessons Learnt from the Use of Cytokines and Cytokine Antagonists. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 921-922.	1.2	0
7	Use of a Standardized MxA Protein Measurement-Based Assay for Validation of Assays for the Assessment of Neutralizing Antibodies Against Interferon- β . <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 660-671.	1.2	17
8	Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 530-538.	2.0	104
9	Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals. <i>Bioanalysis</i> , 2012, 4, 2179-2190.	1.5	7
10	Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10486-10491.	7.1	30
11	Overcoming immunogenicity associated with the use of biopharmaceuticals. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 623-631.	3.1	23
12	Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF α antagonists. <i>Journal of Immunological Methods</i> , 2011, 373, 229-239.	1.4	91
13	Immunogenicity and other problems associated with the use of biopharmaceuticals. <i>Therapeutic Advances in Drug Safety</i> , 2011, 2, 113-128.	2.4	98
14	One-step assay for quantification of neutralizing antibodies to biopharmaceuticals. <i>Journal of Immunological Methods</i> , 2010, 356, 18-28.	1.4	16
15	Concomitant type I IFN receptor α -triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T α cell expansion. <i>European Journal of Immunology</i> , 2010, 40, 2769-2777.	2.9	29
16	Safety, Tolerability, and Immunogenicity of Interferons. <i>Pharmaceuticals</i> , 2010, 3, 1162-1186.	3.8	24
17	WHO international cytokine standards and reference preparations. <i>Journal of Leukocyte Biology</i> , 2010, 88, 425-426.	3.3	1
18	Type I Interferons Mediate the Innate Cytokine Response to Recombinant Fowlpox Virus but Not the Induction of Plasmacytoid Dendritic Cell-Dependent Adaptive Immunity. <i>Journal of Virology</i> , 2010, 84, 6549-6563.	3.4	18

#	ARTICLE	IF	CITATIONS
19	Adjuvant Activity of Cytokines. <i>Methods in Molecular Biology</i> , 2010, 626, 287-309.	0.9	83
20	World Health Organization International Cytokine Standards and Reference Preparations. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 639-641.	1.2	1
21	Immunotherapy of Multiple Sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 713-714.	1.2	0
22	Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy. <i>Journal of Immunology</i> , 2009, 182, 5217-5224.	0.8	86
23	<i>Cryptosporidium parvum</i> Infection Rapidly Induces a Protective Innate Immune Response Involving Type I Interferon. <i>Journal of Infectious Diseases</i> , 2009, 200, 1548-1555.	4.0	56
24	Effect of sublingual administration of interferon- α on the immune response to influenza vaccination in institutionalized elderly individuals. <i>Vaccine</i> , 2008, 26, 4073-4079.	3.8	22
25	Adjuvant activity of type I interferons. <i>Biological Chemistry</i> , 2008, 389, 541-545.	2.5	53
26	Targeting the Effector Site with IFN- α -Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors. <i>Journal of Immunology</i> , 2008, 180, 1535-1544.	0.8	59
27	Targeting Poly(I:C) to the TLR3-Independent Pathway Boosts Effector CD8 T Cell Differentiation through IFN- α . <i>Journal of Immunology</i> , 2008, 181, 7670-7680.	0.8	64
28	Involvement of the Gab2 scaffolding adapter in type I interferon signalling. <i>Cellular Signalling</i> , 2007, 19, 2080-2087.	3.6	12
29	Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors. <i>European Cytokine Network</i> , 2007, 18, 108-14.	2.0	14
30	Infection by ME7 prion is not modified in transgenic mice expressing the yeast chaperone Hsp104 in neurons. <i>Neuroscience Letters</i> , 2006, 405, 181-185.	2.1	22
31	Adjuvant activity of interferon alpha: mechanism(s) of action. <i>Vaccine</i> , 2006, 24, S46-S47.	3.8	28
32	SCRG1, a Potential Marker of Autophagy in TSE. <i>Autophagy</i> , 2006, 2, 58-60.	9.1	25
33	TL1A: A mediator of gut inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 8303-8304.	7.1	25
34	Scrg1 is induced in TSE and brain injuries, and associated with autophagy. <i>European Journal of Neuroscience</i> , 2005, 22, 133-146.	2.6	32
35	Interferons α and β induce p53-dependent and p53-independent apoptosis, respectively. <i>Oncogene</i> , 2005, 24, 605-615.	5.9	89
36	Hypervirulent M. tuberculosis Beijing Strains Upregulate Type I IFNs and Increase Expression of Negative Regulators of the Jak-Stat Pathway. <i>Journal of Interferon and Cytokine Research</i> , 2005, 25, 694-701.	1.2	267

#	ARTICLE	IF	CITATIONS
37	Identification of Residues of the IFNAR1 Chain of the Type I Human Interferon Receptor Critical for Ligand Binding and Biological Activity. <i>Biochemistry</i> , 2004, 43, 12498-12512.	2.5	36
38	An Essential Role for IFN- β in the Overexpression of Fas Ligand on MRL/lpr Lymphocytes and on Their Spontaneous Fas-Mediated Cytotoxic Potential. <i>Journal of Interferon and Cytokine Research</i> , 2004, 24, 717-728.	1.2	16
39	An Essential Role for IFN- β in the Overexpression of Fas Ligand on MRL/lpr Lymphocytes and on Their Spontaneous Fas-Mediated Cytotoxic Potential. <i>Journal of Interferon and Cytokine Research</i> , 2004, 24, 717-728.	1.2	2
40	Scrg1, a novel protein of the CNS is targeted to the large dense-core vesicles in neuronal cells. <i>European Journal of Neuroscience</i> , 2003, 18, 2449-2459.	2.6	18
41	Mycobacterial Antigens Exacerbate Disease Manifestations in Mycobacterium tuberculosis-Infected Mice. <i>Infection and Immunity</i> , 2002, 70, 2100-2107.	2.2	88
42	Molecular Cloning of ADIR, a Novel Interferon Responsive Gene Encoding a Protein Related to the Torsins. <i>Genomics</i> , 2002, 79, 315-325.	2.9	34
43	GAAP1: a transcriptional activator of p53 and IRF1 possesses pro-apoptotic activity. <i>EMBO Reports</i> , 2002, 3, 153-158.	4.5	18
44	Effect of Oromucosal Administration of IFN- β on Allergic Sensitization and the Hypersensitive Inflammatory Response in Animals Sensitized to Ragweed Pollen. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 583-593.	1.2	15
45	Induction of Tolerance to Recombinant Therapeutic Proteins. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 1031-1038.	1.2	11
46	Oromucosal Interferon Therapy: Relationship Between Antiviral Activity and Viral Load. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 575-581.	1.2	14
47	Efficacy and Safety of Orally/Sublingually, Intranasally, and Intraperitoneally Administered Recombinant Murine Interferon in the Treatment of Murine Encephalomyocarditis Virus. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 539-545.	1.2	2
48	Mouse Scrapie Responsive Gene 1 (Scrg1): Genomic Organization, Physical Linkage to Sap30, Genetic Mapping on Chromosome 8, and Expression in Neuronal Primary Cell Cultures. <i>Genomics</i> , 2000, 70, 140-149.	2.9	14
49	Enhanced levels of scrapie responsive gene mRNA in BSE-infected mouse brain. <i>Molecular Brain Research</i> , 2000, 76, 173-179.	2.3	35
50	Interleukin-6 repression is associated with a distinctive chromatin structure of the gene. <i>Nucleic Acids Research</i> , 1999, 27, 4483-4490.	14.5	25
51	Oromucosal Interferon Therapy: Marked Antiviral and Antitumor Activity. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 145-155.	1.2	50
52	Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 911-921.	1.2	21
53	Oromucosal Interferon Therapy: Pharmacokinetics and Pharmacodynamics. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 157-169.	1.2	32
54	Improvement of Normothermic Rat Liver Ischemia/Reperfusion by Muramyl Dipeptide. <i>Journal of Surgical Research</i> , 1998, 80, 339-344.	1.6	13

#	ARTICLE	IF	CITATIONS
55	Characterization of the Human Analogue of a Scrapie-responsive Gene. <i>Journal of Biological Chemistry</i> , 1998, 273, 18015-18018.	3.4	25
56	Gene Expression in Scrapie. <i>Journal of Biological Chemistry</i> , 1998, 273, 7691-7697.	3.4	139
57	Prolonged Allograft Survival in Cynomolgus Monkeys Treated with a Monoclonal Antibody to the Human Type I Interferon Receptor and Low Doses of Cyclosporine. <i>Journal of Interferon and Cytokine Research</i> , 1998, 18, 273-284.	1.2	14
58	Identification of a Novel Transcriptional Regulatory Element Common to the p53 and Interferon Regulatory Factor 1 Genes. <i>Journal of Biological Chemistry</i> , 1997, 272, 29801-29809.	3.4	12
59	Comparative study of the expression of cellular proteins in uninfected and HIV infected U937 cells using two dimensional SDS polyacrylamide gel electrophoresis. <i>Chemico-Biological Interactions</i> , 1997, 103, 179-186.	4.0	6
60	Molecular mechanisms regulating induction of interleukin-6 gene transcription by interferon- β . <i>European Journal of Immunology</i> , 1997, 27, 3022-3030.	2.9	55
61	The Relationship Between the Interferon β Response and Viral Burden in Primary SIV Infection. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1273-1278.	1.1	45
62	Constitutive expression of specific interferon isotypes in peripheral blood leukocytes from normal individuals and in promonocytic U937 cells. <i>Journal of Leukocyte Biology</i> , 1996, 60, 137-146.	3.3	23
63	The β Enhancer of the Human Interleukin-6 Promoter Is Necessary and Sufficient to Confer an IL-1 β and TNF- β Response in Transfected Human Cell Lines: Requirement for Members of the C/EBP Family for Activity. <i>Journal of Interferon and Cytokine Research</i> , 1996, 16, 783-798.	1.2	32
64	The essential role of endogenous IFN β / β in the anti-metastatic action of sensitized T lymphocytes in mice injected with friend erythroleukemia cells. <i>International Journal of Cancer</i> , 1995, 63, 726-731.	5.1	24
65	Characterization of a Domain of a Human Type I Interferon Receptor Protein Involved in Ligand Binding. <i>Journal of Interferon and Cytokine Research</i> , 1995, 15, 205-211.	1.2	21
66	Interferon-Resistant Daudi Cells Are Deficient in Interferon- β -Induced ISGF3 β Activation, but Remain Sensitive to the Interferon- β -Induced Increase in ISGF3 β Content. <i>Journal of Interferon Research</i> , 1993, 13, 377-383.	1.2	8
67	Specific Interferon Genes Are Expressed in Individual Cells in the Peritoneum and Bone Marrow of Normal Mice. <i>Journal of Interferon Research</i> , 1992, 12, 27-34.	1.2	7
68	Tandem Repeat Polymers of a Critical Region of the Human Interferon- β Promoter Exhibit a Marked Constitutive Activity and Enhanced Responsiveness to Transcriptional Regulators in Transfected HeLa Cells. <i>Journal of Interferon Research</i> , 1992, 12, 377-387.	1.2	0
69	Expression of the Genes of Class I Interferons and Interleukin-6 in Individual Cells. <i>Journal of Interferon Research</i> , 1991, 11, 91-103.	1.2	10
70	Genes for Interleukin-1, Interleukin-6, and Tumor Necrosis Factor are Expressed at Markedly Reduced Levels in the Livers of Patients with Severe Liver Disease. <i>Autoimmunity</i> , 1991, 10, 297-310.	2.6	25
71	Expression of IL-6 in Normal Individuals and in Patients with Autoimmune Disease. <i>Annals of the New York Academy of Sciences</i> , 1989, 557, 363-373.	3.8	2
72	Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. IV. Definition of optimal treatment regimens. <i>International Journal of Cancer</i> , 1986, 38, 251-257.	5.1	25

#	ARTICLE	IF	CITATIONS
73	Cyclic GMP levels in interferon treated cells. Antiviral Research, 1985, 5, 127-135.	4.1	0
74	Natural killer cell cytotoxicity: Role of calmodulin. Biochemical and Biophysical Research Communications, 1984, 121, 478-486.	2.1	11
75	Presence of an abnormal β 2-microglobulin mRNA in Daudi cells: Induction by interferon. Immunogenetics, 1983, 17, 125-131.	2.4	29
76	Effect of anti-interferon serum of influenza virus infection in mice. Antiviral Research, 1983, 3, 59-65.	4.1	35
77	Antitumor Effect of Combined Interferon and Hyperthermia in Mice. Experimental Biology and Medicine, 1982, 169, 413-415.	2.4	17
78	Interferon Enhancement of Natural Killer Cell Cytotoxicity: Role of Cyclic Nucleotides. Journal of Interferon Research, 1982, 2, 549-561.	1.2	6
79	Rapid increase in guanosine 3',5'-cyclic-monophosphate in interferon-treated mouse leukemia L1210 cells: Relationship to the development of the antiviral state and inhibition of cell multiplication. Virology, 1981, 115, 272-281.	2.4	30
80	[47] Use of chemostat culture for the study of the effect of interferon on tumor cell multiplication. Methods in Enzymology, 1981, 79, 391-404.	1.0	3
81	The Cultivation of Animal Cells in the Chemostat: Application to the Study of Tumor Cell Multiplication. Advances in Cancer Research, 1980, 33, 1-37.	5.0	16
82	Correlation between growth rate, cell density, and intracellular concentrations of cyclic nucleotides in chemostat cultures of mouse L1210 cells. Journal of Cellular Physiology, 1980, 105, 363-367.	4.1	6
83	Induction of Epstein-Barr virus early antigen by phytohaemagglutinin in the presence of 5-iodo-2'-deoxyuridine: Application to EBV serology. Journal of Immunological Methods, 1980, 34, 23-29.	1.4	4
84	INTERFERON-INDUCED DISEASE IN MICE AND RATS. Annals of the New York Academy of Sciences, 1980, 350, 12-20.	3.8	52
85	THE EFFECT OF INTERFERON ON CYCLIC NUCLEOTIDES. Annals of the New York Academy of Sciences, 1980, 350, 266-278.	3.8	18
86	ELECTROPHORETICALLY PURE MOUSE INTERFERON EXERTS MULTIPLE BIOLOGICAL EFFECTS. Annals of the New York Academy of Sciences, 1980, 350, 347-353.	3.8	7
87	Activation of latent Epstein-Barr virus by antibody to human IgM. Nature, 1978, 276, 270-272.	27.8	185
88	Role of endogenous interferon in the anti-tumor effect of poly I:C and statolon as demonstrated by the use of anti-mouse interferon serum. International Journal of Cancer, 1978, 21, 72-77.	5.1	39
89	Inhibition by Interferon of Thymidine Uptake in Chemostat Cultures of L1210 Cells. Intervirology, 1978, 9, 243-252.	2.8	75
90	Marked enhancement of interferon production in 5-bromodeoxyuridine treated human lymphoblastoid cells. Nature, 1977, 267, 455-457.	27.8	56

#	ARTICLE	IF	CITATIONS
91	Identification of the cell multiplication inhibitory factors in interferon preparations as interferons. Nature, 1976, 262, 300-302.	27.8	139
92	Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature, 1976, 263, 420-422.	27.8	124
93	Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in akr mice. International Journal of Cancer, 1976, 17, 647-651.	5.1	49
94	Lethality of interferon preparations for newborn mice. Nature, 1975, 258, 76-78.	27.8	131
95	A Method for the Large Scale Production of Potent Interferon Preparations. Experimental Biology and Medicine, 1974, 146, 809-815.	2.4	167
96	Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature, 1974, 251, 543-545.	27.8	191
97	Interferon and Cell Division VII. Inhibitory Effect of Highly Purified Interferon Preparations on the Multiplication of Leukemia L 1210 Cells. Experimental Biology and Medicine, 1973, 142, 7-10.	2.4	31